/PRNewswire/ Neurimmune AG today announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca s Rare.
/PRNewswire/ Neurimmune AG today announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca s Rare.
Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006 Zurich, Switzerland, January 7, 2022 – Neurimmune AG today announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Dise.
Aducanumab is approved in the United States, but the EU's regulatory authority is blocking its use. The drug is designed to combat amyloid beta plaques in the brain that are typical of Alzheimer's disease.
The drug aducanumab could be approved in the US and EU soon. It effectively combats the amyloid beta plaques in the brain that are indicative of Alzheimer's disease. But does it also slow down memory loss?